Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06863233 · ClinicalTrials.gov registry record · Phase 1
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
A Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 7
- Study locations
NCT06863233 is a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 5 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT06863233, a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
Conditions Studied
Interventions
- DRUG Zirconium Zr 89 crefmirlimab berdoxam
- DIAGNOSTIC_TEST PET/CT Scan
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only) - Commack
- Memorial Sloan Kettering Westchester (Consent only) - Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activities) - New York
- Memorial Sloan Kettering Cancer Center @ Nassau (Consent only) - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Consent Only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent Only) - Middletown
- Memorial Sloan Kettering Bergen (Consent Only) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2028-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06863233
The ClinicalTrials.gov registry entry for NCT06863233 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Zirconium Zr 89 crefmirlimab berdoxam is the first listed.
NCT06863233 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06863233 about?
NCT06863233 is a clinical study titled "A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer". The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
What is the current status of trial NCT06863233?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2025-03-03. Estimated completion is 2028-03-03.
What conditions does trial NCT06863233 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Metastatic Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT06863233?
The interventions under investigation include: Zirconium Zr 89 crefmirlimab berdoxam (DRUG), PET/CT Scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06863233?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06863233 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.